Why Choose ChemDiv?

  • 25 years experience and 2500 customers worldwide
  • Premium R&D CRO based in USA with global reach
  • Seasoned project managers
  • Extensive Academic partnerships
  • Flexible business models
  • Industry's largest ever-greening stock compound inventory
  • Ongoing investments in novel proprietary chemistry and discovery platforms

Our News

SAN DIEGO, February 1, 2017 /PRNewswire/ -- ChemDiv Inc. to Conduct Medicinal Chemistry Studies on Compounds for Modulating Check Point NR2F6 Regen BioPharma Inc. (RGBP), (RGBPP) has entered into a Master Agreement with ChemDiv, Inc. to begin the ... Read More
See All News About Us >

Pharma News

OSAKA, Japan and FLORHAM PARK, N.J. and STAMFORD, Conn., March 23, 2017 /PRNewswire/ -- Shionogi Inc. and Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Symproic® (naldemedine) 0.2 mg tablets C-II as ... Read More
See All Pharma News >

Featured Structures

Compound S511-0490 represents a new series of helix-mimetics possessing high drug-like and natural product-like properties.
This series is included in several of our new focused and special libraries.